| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | NHE3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SLC9A3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC9A3抗体的3篇参考文献示例(注：以下为虚构示例，实际文献需通过学术数据库查询)：
1. **文献名称**：*"SLC9A3 Expression and Localization in Inflammatory Bowel Disease"*
**作者**：Smith J, et al.
**摘要**：研究通过SLC9A3特异性抗体进行免疫组化和Western blot分析，发现IBD患者结肠上皮中SLC9A3蛋白表达显著降低，提示其功能缺陷可能与肠道钠吸收障碍及炎症相关。
2. **文献名称**：*"Role of SLC9A3 in Intestinal Sodium Transport: Insights from Knockout Mice"*
**作者**：Wang L, et al.
**摘要**：利用SLC9A3抗体检测基因敲除小鼠肠道组织，证实SLC9A3缺失导致钠离子转运功能受损，并诱发慢性腹泻，揭示了其在维持肠道离子稳态中的关键作用。
3. **文献名称**：*"Antibiotic-Induced Dysregulation of SLC9A3 in Gut Epithelium"*
**作者**：Garcia R, et al.
**摘要**：通过免疫荧光和流式细胞术结合SLC9A3抗体，发现抗生素处理会下调肠道上皮细胞SLC9A3表达，可能通过改变微生物群-宿主互作影响钠吸收。
如需真实文献，建议通过 **PubMed** 或 **Google Scholar** 检索关键词 "SLC9A3 antibody" + "NHE3" + "应用领域(如IBD、癌症等)"。
The SLC9A3 antibody targets the solute carrier family 9 member A3 (SLC9A3), a protein encoded by the SLC9A3 gene. This gene product, also known as sodium-hydrogen exchanger 3 (NHE3), is a transmembrane protein primarily expressed in the intestinal and renal epithelial cells. It regulates sodium absorption and pH homeostasis by exchanging intracellular protons for extracellular sodium ions. Dysregulation of SLC9A3 has been implicated in gastrointestinal disorders (e.g., congenital sodium diarrhea), cystic fibrosis-related complications, and hypertension, making it a focus in studies of electrolyte balance and epithelial transport mechanisms.
SLC9A3 antibodies are essential tools for detecting and quantifying NHE3 expression in research settings. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study protein localization, expression patterns, and functional alterations in disease models. Commercially available antibodies are typically raised against specific epitopes, such as the C-terminal or N-terminal regions, and validated for specificity using knockout controls or siRNA-mediated silencing. Researchers also employ these antibodies to explore SLC9A3’s role in pathological conditions, including metabolic acidosis, diabetic nephropathy, and inflammatory bowel disease. Recent studies highlight its interaction with signaling pathways (e.g., cAMP/PKA) and microbial toxins, emphasizing its therapeutic potential. Rigorous validation ensures minimal cross-reactivity with other NHE isoforms, enhancing reliability in experimental outcomes.
×
